Publication:
Cladribine Versus Fingolimod, Natalizumab and Interferon Β for Multiple Sclerosis

Simple item page
dc.authorwosidKermode, Allan/G-3568-2019
dc.authorwosidTrojano, Maria/Abt-3098-2022
dc.authorwosidPrat, Aleix/P-8561-2014
dc.authorwosidSolaro, Claudio/Aal-2402-2021
dc.authorwosidTerzi̇, Murat/Aaa-1284-2021
dc.authorwosidSlee, Mark/J-4731-2015
dc.authorwosidHavrdova, Eva/P-4892-2017
dc.contributor.authorKalincik, T.
dc.contributor.authorJokubaitis, V.
dc.contributor.authorSpelman, T.
dc.contributor.authorHorakova, D.
dc.contributor.authorHavrdova, E.
dc.contributor.authorTrojano, M.
dc.contributor.authorButzkueven, H.
dc.date.accessioned2025-12-11T00:49:15Z
dc.date.issued2017
dc.departmentOndokuz Mayıs Üniversitesien_US
dc.department-temp[Kalincik, T.] Royal Melbourne Hosp, Dept Neurol, CORe, Melbourne, Vic, Australia; [Jokubaitis, V.; Spelman, T.; Butzkueven, H.] Univ Melbourne, Dept Med, Melbourne, Vic, Australia; [Horakova, D.; Havrdova, E.] Gen Univ Hosp, Dept Neurol, Prague, Czech Republic; [Horakova, D.; Havrdova, E.] Gen Univ Hosp, Ctr Clin Neurosci, Prague, Czech Republic; [Horakova, D.; Havrdova, E.] Charles Univ Prague, Fac Med 1, Prague, Czech Republic; [Trojano, M.] Univ Bari, Dept Basic Med Sci Neurosci & Sense Organs, Bari, Italy; [Lechner-Scott, J.] Univ Newcastle, Sch Med & Publ Hlth, Newcastle, NSW, Australia; [Lugaresi, A.] Univ Bologna, Dept Biomed & Neuromotor Sci, Bologna, Italy; [Prat, A.; Girard, M.; Duquette, P.] Hop Notre Dame De Bon Secours, Montreal, PQ, Canada; [Grammond, P.] CISSS Chaudiere Appalache, Levis, PQ, Canada; [Solaro, C.] Osped PA Micone, Genoa, Italy; [Grand'Maison, F.] Neuro Rive Sud, Quebec City, PQ, Canada; [Hupperts, R.] Zuyderland Ziekenhuis, Sittard, Netherlands; [Prevost, J.] CSSS St JErUme, St Jerome, PQ, Canada; [Sola, P.; Ferraro, D.] Univ Modena, Dept Biomed Metab & Neurosci, Modena, Italy; [Terzi, M.] 19 Mayis Univ, Fac Med, Samsun, Turkey; [Butler, E.] Monash Med Ctr, Melbourne, Vic, Australia; [Slee, M.] Flinders Univ S Australia, Adelaide, SA, Australia; [Kermode, A.; Fabis-Pedrini, M.] Univ Western Australia, Perth, WA, Australia; [McCombe, P.] Univ Queensland, Brisbane, Qld, Australia; [Barnett, M.] Univ Sydney, Brain & Mind Ctr, Sydney, NSW, Australia; [Shaw, C.] Geelong Hosp, Geelong, Vic, Australia; [Hodgkinson, S.] Liverpool Hosp, Sydney, NSW, Australiaen_US
dc.description.sponsorshipBiogen; Merck; Teva; Novartis; Charles University in Prague [PRVOUK-P26/LF1/4]; Czech Ministry of Health [NT13237-4/2012]; Actelion; Receptos; Genzyme; Biogen-Idec; Bayer; Sanofi; Fondazione Italiana Sclerosi Multipla (FISM); Teva Canada Innovation; Genzyme Sanofi; EMD; Canadian Institutes of Health Research; Teva-Neuroscience; Canadian Multiple sclerosis society; Teva Neurosciences; Mitsubishi; ONO Pharmaceuticals; Bayer-Schering; Bayer Scheringen_US
dc.description.sponsorshipDana Horakova received speaker honoraria and consulting fees from Biogen, Merck, Teva and Novartis, as well as support for research activities from Biogen and research grants from Charles University in Prague (PRVOUK-P26/LF1/4 and Czech Ministry of Health (NT13237-4/2012). Eva Havrdova received speaker honoraria and consultant fees from Actelion, Biogen, Merck, Novartis, Receptos, Genzyme and Teva, as well as support for research activities from Biogen, and Merck. Maria Trojano received speaker honoraria from Biogen-Idec, Bayer-Schering, Sanofi Aventis, Merck, Teva, Novartis and Almirall; has received research grants for her Institution from Biogen-Idec, Merck, and Novartis. Alessandra Lugaresi is a Bayer, Biogen, Genzyme, Merck Advisory Board Member. She received travel grants and honoraria from Bayer, Biogen, Merck, Novartis, Sanofi, Teva and Fondazione Italiana Sclerosi Multipla (FISM). Her institution received research grants from Bayer, Biogen, Merck, Novartis, Sanofi, Teva and Fondazione Italiana Sclerosi Multipla (FISM). Alexandre Prat did not declare any competing interests. Marc Girard received consulting fees from Teva Canada Innovation, Biogen, Novartis and Genzyme Sanofi; lecture payments from Teva Canada Innovation, Novartis and EMD. He has also received a research grant from Canadian Institutes of Health Research. Pierre Grammond is a Novartis, Teva-neuroscience, Biogen and Genzyme advisory board member, consultant for Merck, received payments for lectures by Merck, Teva-Neuroscience and Canadian Multiple sclerosis society, and received grants for travel from Teva-Neuroscience and Novartis. Francois Grand'Maison received honoraria or research funding from Biogen, Genzyme, Novartis, Teva Neurosciences, Mitsubishi and ONO Pharmaceuticals. Murat Terzi received travel grants from Merck, Novartis, Bayer-Schering, Merck and Teva; has participated in clinical trials by Sanofi Aventis, Roche and Novartis. Suzanne Hodgkinson received honoraria and consulting fees from Novartis, Bayer Schering and Sanofi, and travel grants from Novartis, Biogen Idec and Bayer Schering.en_US
dc.description.woscitationindexScience Citation Index Expanded - Conference Proceedings Citation Index - Science
dc.identifier.endpage597en_US
dc.identifier.issn1352-4585
dc.identifier.issn1477-0970
dc.identifier.scopusqualityQ1
dc.identifier.startpage596en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12712/39580
dc.identifier.volume23en_US
dc.identifier.wosWOS:000413730203308
dc.identifier.wosqualityQ1
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofMultiple Sclerosis Journalen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleCladribine Versus Fingolimod, Natalizumab and Interferon Β for Multiple Sclerosisen_US
dc.typeConference Objecten_US
dspace.entity.typePublication

Files

Collections

WoS İndeksli Yayınlar Koleksiyonu